Freeze-thaw comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-10. Numbers and descriptions here follow the published literature rather than marketing material.
Stability testing examines how peptide purity changes over time under defined conditions. Accelerated studies use elevated temperatures and humidity to predict degradation pathways, while long-term studies store samples at recommended temperatures. Common degradation reactions include oxidation of methionine, deamidation of asparagine, and hydrolysis of peptide bonds. The results inform expiration dates and storage recommendations for research materials. Lyophilized peptides are generally more stable than solutions, but both forms can degrade if exposed to moisture, oxygen, or repeated freeze-thaw cycles.
Impurity profiling identifies and quantifies substances that coexist with the target peptide. These include deletion sequences, truncated peptides, oxidized variants, and residual protecting groups from synthesis. Reversed-phase chromatography can separate many of these impurities, but co-elution remains a challenge for closely related species. Mass spectrometry helps assign identities to impurity peaks, and impurity limits are often set as area percentages relative to the main peak. Regulatory guidelines for research-grade peptides are less strict than those for therapeutic products, so specifications vary by supplier.
Quality control for peptides involves setting specifications for identity, purity, and counterion content. Batches are tested against these specifications before release. Purity specifications often require a minimum area percentage by high-performance liquid chromatography, such as 95% or 98%, depending on the intended application. Additional tests may include water content, acetate or trifluoroacetate content, and residual solvents. These parameters affect the net peptide content and the accuracy of subsequent laboratory experiments.
Handling practices reduce the risk of contamination and degradation. Hygroscopic peptides should be equilibrated to room temperature before opening to prevent condensation on the powder. Weighing and reconstitution in a controlled environment limit exposure to moisture and airborne particles. Aliquotting reconstituted solutions avoids repeated freeze-thaw cycles that can cause aggregation or precipitation. When a purity specification is not met, investigation may consider synthesis byproducts, purification losses, storage conditions, and analytical variability rather than a single cause.
Peptide purity can change during storage, handling, and reconstitution, and lyophilized peptides are generally more stable than solutions because water promotes hydrolysis and aggregation. Residual moisture, oxygen, and trace metals can accelerate degradation even in solid form. Temperature fluctuations during shipping may cause condensation and local moisture uptake. Quality control therefore includes appearance, water content, and analytical testing before and after storage challenges. Peptides containing cysteine, methionine, or tryptophan are especially susceptible to oxidation, while asparagine and glutamine residues can deamidate under neutral or alkaline conditions.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature (lyophilized) | -20 °C | Long-term storage; -80 °C for extended periods |
| Typical storage temperature (solution) | -80 °C | Avoid repeated freeze-thaw; aliquot before freezing |
| Common degradation pathway | Oxidation of methionine | Affects peptides containing methionine; accelerated by oxygen |
| Common counterion | Trifluoroacetate | From HPLC purification; acetate also common |
| Purity specification (research grade) | ≥95% by HPLC area | Higher grades may require ≥98%; method-dependent |
Other methods address specific purity concerns. Amino acid analysis gives compositional data after hydrolysis, while capillary electrophoresis separates by charge-to-mass ratio. Karl Fischer titration measures residual water, and gas chromatography can detect residual solvents. Nuclear magnetic resonance can identify organic impurities but is less sensitive for trace levels. No single test covers all possible impurities, so purity testing usually combines orthogonal methods and reports the conditions used. The choice of methods is guided by the impurity classes of interest.
Reverse-phase high-performance liquid chromatography (RP-HPLC) is widely used to estimate peptide purity. It separates components by hydrophobicity on a column with a water-organic mobile phase. Ultraviolet absorbance at 214 nm or 220 nm detects peptide bonds. The main peak area as a percentage of total peak area gives a purity figure. This figure depends on column, gradient, wavelength, and how peaks are integrated, so it is method-specific rather than absolute.
Mass spectrometry provides complementary information about molecular identity and certain impurities. Electrospray ionization and matrix-assisted laser desorption/ionization are common ionization techniques for peptides. A measured mass close to the expected value supports correct sequence length and modifications, while extra mass signals can reveal truncations, adducts, or incomplete deprotection. Mass spectrometry alone is not a quantitative purity assay, because ionization efficiency varies between compounds. Coupling liquid chromatography to mass spectrometry links retention time with mass and helps assign peaks that ultraviolet detection records.
Orthogonal separation methods address impurities that RP-HPLC may not resolve. Size-exclusion chromatography detects aggregates and higher-order species, while ion-exchange chromatography separates charge variants. Capillary electrophoresis can assess charge-to-mass ratios and, in some formats, size-based impurities. Amino acid analysis and nitrogen determination estimate peptide content rather than chromatographic purity. Because each technique has a different selectivity, a complete purity profile usually combines results from more than one method. The choice of method depends on the impurity classes of concern.
Reversed-phase high-performance liquid chromatography (RP-HPLC) is widely used to estimate peptide purity. Separation depends on interactions between peptide residues and a hydrophobic stationary phase, with gradients of water and organic solvent. Ultraviolet detection near 214 nm responds to the peptide backbone and to many related impurities. The resulting chromatogram is often expressed as area percent, which reports the proportion of peak area assigned to the main component. Different columns, gradients, and wavelengths can produce different purity values for the same material.
Peptide purity specifications describe the minimum acceptable result from a defined test. A certificate of analysis may list HPLC purity, mass spectrometry identity, appearance, and counterion content. Specifications are method-dependent, so a value obtained with one gradient or wavelength may differ from another. For research use, common thresholds include 95% and 98% by RP-HPLC, but the appropriate limit depends on the application. The specification should always name the analytical method and acceptance criterion.
Quality control includes system suitability, blank injections, and reference standards. System suitability checks column performance and retention time reproducibility, while blank runs detect carryover or mobile-phase contaminants. Reference standards help calibrate retention time and detector response. Without these controls, a purity value is difficult to compare across laboratories or over time. Documentation of instrument settings and integration parameters is also part of quality control, and acceptance criteria should be set before samples are analyzed.
Quality control for peptides begins with a documented specification that states the required purity, identity, and appearance. Suppliers often release research-grade material at 95% or greater by HPLC area, but this threshold is not universal. A certificate of analysis typically records the lot number, sequence, test methods, and measured values. The document allows a user to compare batches and to trace deviations. Specifications should match the intended use rather than a generic label.
Storage and handling conditions affect both peptide stability and the accuracy of later purity tests. Lyophilized powders are commonly kept desiccated at -20 °C or below, while reconstituted solutions require a defined buffer, pH, and temperature range. Repeated freeze-thaw cycles can promote aggregation, oxidation, or hydrolysis over time. Each cycle may alter the chromatogram and complicate comparison with earlier results. Stability data, when available, should guide handling intervals and solvent choice.
Independent verification is used when a supplier result needs confirmation or when a material supports regulated work. A second laboratory can repeat reverse-phase HPLC and mass spectrometry on the same sample. Discrepancies may arise from different columns, gradients, detection wavelengths, or sample preparation. Moisture uptake and counterion content can lower net peptide mass without changing area percent. Documentation of methods and raw data helps distinguish analytical variation from a true quality difference.
CPPs found applications as transporters of contrast agents across plasma membranes. These contrast agents are able to label the tumor cells, making the compounds important tools in cancer diagnosis; they are also used in in vivo and in vitro cellular experiments. The most important classes of CPP are isolated from viruses, such as TAT (transactivated-transcription) derived from HIV-1, penetratin, and transportan. The most widely used CPPs are based on TAT derivatives. TAT is an arginine-rich CPP. Several improvements for this substrate includes the usage of unnatural β or γ amino acids. This strategy offers multiple advantages, such resistance to proteolytic degradation, a natural degradation process by which peptide bonds are hydrolyzed to amino acids. Unnatural acid insertion in the peptide chain has multiple advantages. It facilitates the formation of stable foldamers with distinct secondary structure. β-Peptides are conformationally more stable in aqueous solution than naturally occurring peptides, especially for small chains. The secondary structure is reinforced by the presence of a rigid β-amino acid, which contains cyclohexane or cyclopentane fragments. These fragments generate a more rigid structure and influence the opening angle of the foldamer. These features are important for new peptide design. Helical β-peptides mimic antimicrobial activities of host defense peptides. This feature requires the orientation of cationic –hydrophilic on one side, and hydrophobic residues on the other side of the helix.
==== Dopaminergic pathway and reward suppression ==== The mesolimbic dopaminergic circuit functions as a substrate for KOR-regulated mood homeostasis. Dynorphin is synthesized and released by dopamine D1 receptor-expressing medium spiny neurons within the NAcc, establishing a local negative feedback loop that suppresses dopamine release. KOR activation on dopamine terminals inhibits dopamine release through multiple mechanisms: increased potassium conductance via G protein-coupled inward-rectifier potassium (GIRK) channels, suppression of calcium entry, activation of protein kinase C-β (PKCβ), c-Jun N-terminal kinase (JNK), and ERK, as well as facilitation of dopamine transporter (DAT) function through ERK1/2-dependent pathways that accelerate dopamine reuptake. Additionally, KOR activation on local dynorphin-expressing neurons produces presynaptic inhibition of both glutamatergic and GABAergic afferents onto D1 receptor-expressing medium spiny neurons, with preferential suppression of amygdala inputs to D1-MSNs while facilitating integration of hippocampal/amygdalar inputs onto D2 receptor-expressing neurons through disinhibition. In the caudal NAcc shell, KOR-induced dopamine suppression triggers anxiogenic behaviors accompanied by reduced locomotor activity. Conversely, in the rostral shell, KOR activation produces attenuated dopaminergic suppression with diminished aversive behavioral consequences.
Methylnaltrexone bromide, naloxegol, and naldemedine all have similar structures, which is not far away from the chemical structure of morphine and other MOR-agonists. All contain a rigid pentacyclic structure that involves benzene ring (A), tetrahydrofuran ring (B), two cyclohexane rings (C and D) and a piperidine ring (E). The most important functional groups for the biological action of opioids are the hydroxyl group on the phenol, N-methyl group, ether bridge between C4 and C5, the double bond between carbon number C7 and C8 and the hydroxyl groups at C3 and C6. The phenolic ring and its 3-hydroxyl group is vital for the analgesic effects as the removal of the OH group decrease the analgesic activity 10-fold. There is another principle for the hydroxyl group on C6 as the removal enhances its activity. The increased activity is mainly because of the increased lipophilicity and the increased ability to cross the blood–brain barrier. Naldemedine has the hydroxyl group while methylnaltrexone bromide has a ketone group and naloxegol has an ester. The double bond between C7 and C8 is not required for the analgesic effect and reduction of the double bond will increase the activity. None of the antagonists has a double bond in their structure. The N-substituent on the skeleton is thought to determine the pharmacological behavior and its interaction with MOR. It is also thought to play a key role in distinguishing antagonists from agonists. Allyl group, a methylcyclopropyl group or a methylcyclobutyl as N-substituent groups are thought to lead antagonist activity.
== Pathophysiology == The primary characteristic of MASLD is the accumulation of lipids in the liver, largely in the form of triglycerides. However, the mechanisms by which triglycerides accumulate and the reasons that accumulation can lead to liver dysfunction are complex and incompletely understood. MASLD can include steatosis along with varied signs of liver injury: either lobular or portal inflammation (a form of liver injury) or ballooning degeneration. Similarly, MASH can include histological features such as portal inflammation, polymorphonuclear cell infiltrates, Mallory bodies, apoptotic bodies, clear vacuolated nuclei, microvesicular steatosis, megamitochondria, and perisinusoidal fibrosis. Hepatocyte death via apoptosis or necroptosis is increased in MASH compared with simple steatosis, and inflammation is a hallmark of MASH. The degree of inflammation can be correlated to the number of inflammatory foci. Various definitions exist for an inflammatory focus, but one defines it as the presence of more than four mononuclear cells in proximity within the hepatic parenchyma. One debated mechanism proposes that hepatic steatosis progresses to steatosis with inflammation following some further injury, or second hit. Oxidative stress, hormonal imbalances, and mitochondrial abnormalities are potential causes of this "second hit" phenomenon. A further nutrigenomics model named multiple hit extends the second hit model, suggesting that multiple disease biomarkers and factors such as genes and nutrition influence MASLD and MASH progression.
For example, a piece of rock can be inserted into the sample cup and the spectrum measured from it. A useful way of analyzing solid samples without the need for cutting samples uses ATR or attenuated total reflectance spectroscopy. Using this approach, samples are pressed against the face of a single crystal. The infrared radiation passes through the crystal and only interacts with the sample at the interface between the two materials.
Sources: en.wikipedia.org
Chief of the Defence Force – overall senior command officer Chief of the Army Chief of the Air Force Chief of the Navy Chief of the Medical Service (Surgeon General) Staff Divisions under the Chief of Defence Staff included:
After completion of this reaction, glutathione reductase recycles oxidized glutathione back to the reduced form so that it again can be picked up by GSTs. This glutathione system acts as the major reduction-oxidation buffer in aerobic bacterial cells, contributing to the overall reduced cellular environment of the cytosol.
Moxidectin has a longer half-life than ivermectin and may eventually supplant ivermectin as it is a more potent microfilaricide, but there is a need for additional clinical trials, with long-term follow-up, to assess whether moxidectin is safe and effective for treatment of nematode infection in children and women of childbearing potential. There is tentative evidence that ivermectin kills bedbugs, as part of integrated pest management for bedbug infestations. However, such use may require a prolonged course of treatment which is of unclear safety.
The FDA has identified that breast implants may be associated with a rare form of cancer called anaplastic large-cell lymphoma (ALCL), which some experts believe is believed to be associated with chronic bacterial inflammation. Similar ALCL phenomena have been seen with other types of medical implants including vascular access ports, orthopedic hip implants, and jaw (TMJ) implants. The causal association between breast implants and ALCL was conclusively established in December 2013, when researchers at MD Anderson Cancer Center published a study of 60 women with breast implants who were diagnosed with ALCL in the breast. In 2015, plastic surgeons published an article reviewing 37 articles in the literature on 79 patients and collected another 94 unreported cases, resulting in 173 women with breast implants who had developed ALCL of the breast. They concluded that "Breast implant-associated ALCL is a novel manifestation of site- and material-specific lymphoma originating in a specific scar location, presenting a wide array of diverse characteristics and suggesting a multifactorial cause." They stated that "There was no preference for saline or silicone fill or for cosmetic or reconstructive indications." Where implant history was known, the patient had received at least one textured-surface device. In 2016, the World Health Organization (WHO) officially recognized BIA-ALCL. As of April 2022, the FDA has received 1,130 global medical device reports (MDRs) of BIA-ALCL, including 59 deaths.
== Expression and possible function == FAP expression under physiological conditions is very low in the majority of adult tissues. FAP is nevertheless expressed during embryonic development, and in adults in pancreatic alpha cells in multipotent bone marrow stromal cells (BM-MSC) and uterine stroma. FAP expression is high in reactive stromal fibroblasts of epithelial cancers, granulation tissue of healing wounds, and malignant cells of bone and soft tissue sarcomas. FAP is thought to be involved in the control of fibroblast growth or epithelial-mesenchymal interactions during development, tissue repair, and epithelial carcinogenesis. Fibroblast activation protein (FAP) is overexpressed in a vast majority of neoplasms, particularly in more than 90% of epithelial tumors which could be an appropriate target for evaluation of tumor’s molecular and metabolic functions by FAP inhibitor (FAPI) ligands
Sources: en.wikipedia.org
Lyophilized peptides are typically stored at -20 °C or lower, protected from moisture and light. Solutions are often stored at -80 °C and divided into single-use aliquots. Repeated freeze-thaw cycles should be avoided.
Oxidation of methionine and deamidation of asparagine are frequent reactions. Hydrolysis of peptide bonds can occur under acidic or basic conditions. Each pathway produces impurities that reduce purity.
Specifications depend on the intended use and supplier. Common minimums are 95% or 98% by HPLC area percentage. Identity and counterion content are also checked.
Most lyophilized peptides are stored desiccated at -20 °C or lower, protected from light. Some sequences require -80 °C for long-term stability. Storage recommendations depend on sequence, moisture content, and expected duration.